CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 101 enrolled
Drug / intervention
Dexamethasone Intravitreal Implantdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01805323
NCT01805323N/ACompleted
CompareCT.gov

A Retrospective Chart Review of OZURDEX® in Patients With Macular Edema

Allergan·observational·Posted Mar 6, 2013·Updated Apr 17, 2019

In Brief

An observational study evaluating Dexamethasone Intravitreal Implant for Macular Edema. Completed, enrolled 101 participants across 1 site.

Detailed Summary

This retrospective chart review study will describe the history of patients with retinal disease with macular edema to whom OZURDEX® (dexamethasone intravitreal implant) is administered, and assess treatment patterns and visual outcomes. OZURDEX® was previously administered according to general clinical practice.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMacular Edema
CountriesCanada
Collaborators--

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMar 6, 2013
Enrollment StartSep 1, 2012
Primary CompletionApr 15, 2013
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 13.3 years ago

Interventions

Dexamethasone Intravitreal Implantdrug

Dexamethasone Intravitreal Implant (OZURDEX®) previously administered according to general clinical practice.